TY - JOUR
T1 - A Year in the Life of the EU-CardioRNA COST Action
T2 - CA17129 Catalysing Transcriptomics Research in Cardiovascular Disease
AU - Robinson, Emma Louise
AU - Gomes, Clarissa Pedrosa Costa
AU - Potocnjak, Ines
AU - Hellemans, Jan
AU - Betsou, Fay
AU - de Gonzalo-Calvo, David
AU - Stoll, Monika
AU - Yilmaz, Mehmet Birhan
AU - Agg, Bence
AU - Beis, Dimitris
AU - Carmo-Fonseca, Maria
AU - Enguita, Francisco J.
AU - Dogan, Soner
AU - Tuna, Bilge G.
AU - Schroen, Blanche
AU - Ammerlaan, Wim
AU - Kuster, Gabriela M.
AU - Carpusca, Irina
AU - Pedrazzini, Thierry
AU - Emanueli, Costanza
AU - Martelli, Fabio
AU - Devaux, Yvan
AU - EU-CardioRNA COST Action
N1 - Funding Information:
The EU-CardioRNA Cooperation in Science and Technology (COST) Action (CA17129; Catalysing transcriptomics research in cardiovascular disease) is a four-year international interdisciplinary network launched in 2018. COST (European Cooperation in Science and Technology) is funded by the European Union scientific frameworks, including the Horizon 2020. EU-CardioRNA is chaired by Yvan Devaux (Luxembourg Institute of Health, LU) along with Vice Chair Costanza Emanueli (National Heart and Lung Institute, Imperial College London, UK) and the conceptualization and formulation of the network was put together with Clarissa Pedrosa da Costa Gomes (now of Luxembourg Centre for Systems Biology, University of Luxembourg, LU). The Action kicked off in October 2018 with 37 participants from 21 countries. Today, it stands at 179 participants from 36 countries, including international partner countries such as Russian Federation, Singapore, Australia, Armenia and the United States of America.
Publisher Copyright:
© 2020 by the authors.
PY - 2020/6
Y1 - 2020/6
N2 - The EU-CardioRNA Cooperation in Science and Technology (COST) Action is a European-wide consortium established in 2018 with 31 European country members and four associate member countries to build bridges between translational researchers from academia and industry who conduct research on non-coding RNAs, cardiovascular diseases and similar research areas. EU-CardioRNA comprises four core working groups (WG1-4). In the first year since its launch, EU-CardioRNA met biannually to exchange and discuss recent findings in related fields of scientific research, with scientific sessions broadly divided up according to WG. These meetings are also an opportunity to establish interdisciplinary discussion groups, brainstorm ideas and make plans to apply for joint research grants and conduct other scientific activities, including knowledge transfer. Following its launch in Brussels in 2018, three WG meetings have taken place. The first of these in Lisbon, Portugal, the second in Istanbul, Turkey, and the most recent in Maastricht, The Netherlands. Each meeting includes a scientific session from each WG. This meeting report briefly describes the highlights and key take-home messages from each WG session in this first successful year of the EU-CardioRNA COST Action.
AB - The EU-CardioRNA Cooperation in Science and Technology (COST) Action is a European-wide consortium established in 2018 with 31 European country members and four associate member countries to build bridges between translational researchers from academia and industry who conduct research on non-coding RNAs, cardiovascular diseases and similar research areas. EU-CardioRNA comprises four core working groups (WG1-4). In the first year since its launch, EU-CardioRNA met biannually to exchange and discuss recent findings in related fields of scientific research, with scientific sessions broadly divided up according to WG. These meetings are also an opportunity to establish interdisciplinary discussion groups, brainstorm ideas and make plans to apply for joint research grants and conduct other scientific activities, including knowledge transfer. Following its launch in Brussels in 2018, three WG meetings have taken place. The first of these in Lisbon, Portugal, the second in Istanbul, Turkey, and the most recent in Maastricht, The Netherlands. Each meeting includes a scientific session from each WG. This meeting report briefly describes the highlights and key take-home messages from each WG session in this first successful year of the EU-CardioRNA COST Action.
KW - COST Action
KW - network
KW - non-coding RNA
KW - cardiovascular disease
KW - translational research
KW - interdisciplinary
KW - CARDIAC-HYPERTROPHY
KW - HEART
KW - MEDIATOR
KW - RNA
KW - SEX
U2 - 10.3390/ncrna6020017
DO - 10.3390/ncrna6020017
M3 - Article
C2 - 32443579
SN - 2311-553X
VL - 6
JO - Non-coding RNA
JF - Non-coding RNA
IS - 2
M1 - 17
ER -